We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+6.48%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.13B
AUM Growth
+$1.04B
Cap. Flow
+$940M
Cap. Flow %
44.08%
Top 10 Hldgs %
46.5%
Holding
110
New
45
Increased
37
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$98.6M
2
GILD icon
Gilead Sciences
GILD
+$96.5M
3
PFE icon
Pfizer
PFE
+$46.4M
4
JNJ icon
Johnson & Johnson
JNJ
+$33.9M
5
ABBV icon
AbbVie
ABBV
+$26.7M

Top Sells

Rank Stock Value
1
FRX
FOREST LABORATORIES INC
FRX
+$10.9M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$2.11M
3
AEGR
Aegerion Pharmaceuticals
AEGR
+$1K

Sector Composition

Rank Sector Weight
1 Healthcare 81.82%
2 Real Estate 2.39%
3 Financials 1.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ENDP
26
DELISTED
Endo International plc
ENDP
$23M 1.08%
336,215
+210,000
+166% +$13.8M
IBB icon
27
iShares Biotechnology ETF
IBB
$9.52B
$21.7M 1.02%
238,125
+42,573
+22% +$3.74M
NBIX icon
28
Neurocrine Biosciences
NBIX
$18.7B
$20.1M 0.94%
1,281,950
+491,460
+62% +$7.35M
ALKS icon
29
Alkermes
ALKS
$8.39B
$18.7M 0.88%
436,970
+181,000
+71% +$8.11M
CTRX
30
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
$18.3M 0.86%
433,600
+202,600
+88% +$9.21M
CELG
31
CALL
DELISTED
Celgene Corp
CELG
$17.1M 0.8%
+180,800
New +$16.3M
GILD icon
32
CALL
Gilead Sciences
GILD
$163B
$17.1M 0.8%
+160,900
New +$15.8M
GEVA
33
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$15.3M 0.72%
+223,020
New +$16M
MOH icon
34
Molina Healthcare
MOH
$10.2B
$14.7M 0.69%
347,901
+135,360
+64% +$5.99M
MCK icon
35
McKesson
MCK
$101B
$13.2M 0.62%
67,862
– –
SGNT
36
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$12.6M 0.59%
404,731
– –
LLY icon
37
Eli Lilly
LLY
$1.03T
$12.1M 0.57%
+186,918
New +$11.8M
MNTA
38
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$12.1M 0.57%
1,067,575
+714,100
+202% +$8.14M
ALR
39
DELISTED
Alere Inc
ALR
$11.6M 0.54%
297,901
+11,361
+4% +$426K
WELL.PRI
40
DELISTED
Welltower Inc.
WELL.PRI
– –
0
– –
CI icon
41
Cigna
CI
$76.1B
$11.1M 0.52%
+122,251
New +$11.4M
IRWD icon
42
Ironwood Pharmaceuticals
IRWD
$614M
$9.95M 0.47%
917,052
– –
VSTM icon
43
Verastem
VSTM
$536M
$9.8M 0.46%
95,819
+19,250
+25% +$2.02M
EIGR
44
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$9.64M 0.45%
2,157
– –
PRGO icon
45
Perrigo
PRGO
$1.43B
$9.46M 0.44%
62,952
– –
ACOR
46
DELISTED
Acorda Therapeutics
ACOR
$9.26M 0.43%
2,276
+395
+21% +$1.48M
DOC
47
DELISTED
PHYSICIANS REALTY TRUST
DOC
$9.22M 0.43%
+671,702
New +$9.61M
INFI
48
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$9.14M 0.43%
680,746
– –
LTC
49
LTC Properties
LTC
$2.06B
$8.73M 0.41%
+236,618
New +$9.31M
OHI icon
50
Omega Healthcare
OHI
$15B
$8.64M 0.4%
+252,616
New +$9.29M
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2014 Portfolio in Review

As of Q3 2014, Tekla Capital Management held 110 positions worth $2.13B, up 96% from $1.09B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Tekla Capital Management deployed $940M of net new capital in Q3 2014, opening 45 new positions and adding to 37 existing holdings. Its largest new stake was Johnson & Johnson: 327,212 shares worth $34.9M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 89% a quarter earlier, followed by Real Estate and Financials.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $2.11M trimmed.

  • Tekla Capital Management's largest Q3 2014 buy was Johnson & Johnson: 327,212 shares worth $34.9M.
  • Tekla Capital Management added most to Celgene Corp in Q3 2014, an estimated $98.6M increase.
  • Tekla Capital Management's biggest Q3 2014 reduction was Regeneron Pharmaceuticals, cutting an estimated $2.11M.
  • Tekla Capital Management fully exited FOREST LABORATORIES INC in Q3 2014, selling an estimated $10.9M.
  • Tekla Capital Management's ten largest holdings make up 47% of its $2.13B portfolio in Q3 2014.
  • Tekla Capital Management opened 45 new positions and closed 2 in Q3 2014.
  • Tekla Capital Management's portfolio value rose 96% quarter-over-quarter to $2.13B.

Based on Tekla Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.